S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Price:
6.14
CNY
-1.13%
Market Cap:
¥4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
|
CN |
|
H
|
Hangjin Technology Co Ltd
SZSE:000818
|
CN |
|
Janus Henderson Group PLC
NYSE:JHG
|
UK |
|
Netfonds AG
XETRA:NF4
|
DE |
|
Middlesex Water Co
NASDAQ:MSEX
|
US |
Income Statement
Earnings Waterfall
Shanghai MicuRx Pharmaceutical Co Ltd
Shanghai MicuRx Pharmaceutical Co Ltd
Income Statement
Shanghai MicuRx Pharmaceutical Co Ltd
Shanghai MicuRx Pharmaceutical Co Ltd
Currency: CNY
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
5
|
4
|
0
|
0
|
9
|
4
|
6
|
10
|
6
|
10
|
12
|
11
|
13
|
0
|
|
| Revenue |
8
N/A
|
18
+140%
|
28
+53%
|
37
+32%
|
48
+30%
|
55
+14%
|
57
+4%
|
91
+60%
|
82
-10%
|
109
+34%
|
120
+10%
|
130
+9%
|
130
+0%
|
137
+5%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
(1)
|
(2)
|
(4)
|
(7)
|
(9)
|
(11)
|
(11)
|
(17)
|
(15)
|
(20)
|
(22)
|
(22)
|
(22)
|
(22)
|
|
| Gross Profit |
7
N/A
|
16
+134%
|
24
+47%
|
30
+27%
|
39
+30%
|
44
+12%
|
46
+5%
|
74
+61%
|
67
-10%
|
89
+33%
|
98
+10%
|
108
+10%
|
108
+0%
|
114
+6%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(270)
|
(288)
|
(289)
|
(323)
|
(271)
|
(284)
|
(277)
|
(510)
|
(471)
|
(589)
|
(564)
|
(546)
|
(503)
|
(490)
|
|
| Selling, General & Administrative |
(113)
|
(134)
|
(134)
|
(144)
|
(132)
|
(148)
|
(117)
|
(162)
|
(141)
|
(178)
|
(182)
|
(172)
|
(167)
|
(173)
|
|
| Research & Development |
(151)
|
(159)
|
(160)
|
(180)
|
(148)
|
(161)
|
(186)
|
(334)
|
(333)
|
(415)
|
(386)
|
(358)
|
(338)
|
(319)
|
|
| Depreciation & Amortization |
(12)
|
(0)
|
0
|
0
|
(16)
|
0
|
0
|
(15)
|
0
|
0
|
0
|
(15)
|
0
|
0
|
|
| Other Operating Expenses |
5
|
6
|
6
|
2
|
24
|
25
|
25
|
0
|
4
|
4
|
4
|
(2)
|
1
|
2
|
|
| Operating Income |
(264)
N/A
|
(271)
-3%
|
(265)
+2%
|
(292)
-10%
|
(232)
+21%
|
(240)
-3%
|
(231)
+4%
|
(436)
-89%
|
(404)
+7%
|
(500)
-24%
|
(466)
+7%
|
(438)
+6%
|
(395)
+10%
|
(375)
+5%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
7
|
4
|
1
|
9
|
8
|
14
|
10
|
25
|
12
|
14
|
10
|
4
|
1
|
(1)
|
|
| Non-Reccuring Items |
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
30
|
25
|
16
|
8
|
3
|
0
|
(1)
|
(4)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
|
| Pre-Tax Income |
(226)
N/A
|
(242)
-7%
|
(247)
-2%
|
(275)
-11%
|
(220)
+20%
|
(225)
-2%
|
(222)
+2%
|
(415)
-87%
|
(392)
+6%
|
(487)
-24%
|
(456)
+6%
|
(435)
+5%
|
(394)
+9%
|
(377)
+4%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(6)
|
0
|
(11)
|
(12)
|
(6)
|
0
|
(2)
|
|
| Income from Continuing Operations |
(226)
|
(242)
|
(247)
|
(275)
|
(220)
|
(225)
|
(222)
|
(421)
|
(398)
|
(497)
|
(468)
|
(441)
|
(400)
|
(378)
|
|
| Net Income (Common) |
(226)
N/A
|
(242)
-7%
|
(247)
-2%
|
(275)
-11%
|
(220)
+20%
|
(225)
-2%
|
(222)
+2%
|
(421)
-90%
|
(398)
+5%
|
(497)
-25%
|
(468)
+6%
|
(441)
+6%
|
(400)
+9%
|
(378)
+6%
|
|
| EPS (Diluted) |
-0.35
N/A
|
-0.37
-6%
|
-0.38
-3%
|
-0.42
-11%
|
-0.34
+19%
|
-0.34
N/A
|
-0.34
N/A
|
-0.64
-88%
|
-0.61
+5%
|
-0.76
-25%
|
-0.71
+7%
|
-0.67
+6%
|
-0.61
+9%
|
-0.57
+7%
|
|
Switch to:
Switch to:
See Also
Discover More
